Historical iex News Stories

IEX Rally: Analyst Upgrades, New CFO, Buyback Lift

Recent concrete developments for IDEX (IEX) include an RBC price-target raise, the appointment of Sean M. Gillen as CFO, and continued share-repurchase capacity alongside strategic acquisitions—events that together have tightened investor focus on near-term valuation and capital allocation.

IEX Excluded from S&P 500; Industrial Gains Today!

IEX (IDEX Corp.) was not added to the S&P 500 in the March 2026 rebalance, removing index-driven catalysts this week. Sector trends favor automation, data-center demand and health & science technologies — areas where IDEX has exposure. Investors should track order flow, margin trends and upcoming company disclosures for concrete signals.

IDEX Q4: AI Orders Lift Cash; Guidance Cautious Q1

IDEX reported stronger-than-expected Q4 results driven by robust orders—particularly from AI-related Health & Science segments—while management issued conservative 2026 guidance. Solid cash flow and continued share buybacks support shareholder returns even as select industrial end markets remain soft.

IEX Rally: Manufacturing Rebound Boosts DataCenter

Recent U.S. manufacturing indicators and stronger factory orders have provided a favorable tailwind for IDEX Corporation (IEX). Coupled with a robust Q4 2025 showing—driven by data‑center demand in the Health & Science Technologies segment—and heightened institutional interest, IEX is positioned to benefit from renewed industrial capex and targeted end‑market growth.

IDEX Q4 Beat, HST Orders Surge; Guidance Tight

IDEX (IEX) reported a modest Q4 beat driven by a 34% surge in Health & Science Technologies orders and strong free cash flow, but guidance and softer industrial segments kept upside capped. Elevated trading and clear technical levels make the stock sensitive to macro and segment-specific news.

IEX Shares Slip as Manufacturing Data Diverges Now

IDEX (IEX) underperformed the S&P 500 this week amid mixed U.S. industrial signals: factory orders dipped while the ISM manufacturing PMI strengthened. No company-specific catalysts appeared; technicals show weakness but analysts still hold a moderate-buy consensus with upside to the average target.